SG11202011139YA - Protein binding nkg2d, cd16 and a fibroblast activation protein - Google Patents

Protein binding nkg2d, cd16 and a fibroblast activation protein

Info

Publication number
SG11202011139YA
SG11202011139YA SG11202011139YA SG11202011139YA SG11202011139YA SG 11202011139Y A SG11202011139Y A SG 11202011139YA SG 11202011139Y A SG11202011139Y A SG 11202011139YA SG 11202011139Y A SG11202011139Y A SG 11202011139YA SG 11202011139Y A SG11202011139Y A SG 11202011139YA
Authority
SG
Singapore
Prior art keywords
protein
fibroblast activation
binding nkg2d
protein binding
nkg2d
Prior art date
Application number
SG11202011139YA
Inventor
Gregory Chang
Ann Cheung
Jinyan Du
Asya Grinberg
William Haney
Nicolai Wagtmann
Bradley Lunde
Bianka Prinz
Original Assignee
Dragonfly Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dragonfly Therapeutics Inc filed Critical Dragonfly Therapeutics Inc
Publication of SG11202011139YA publication Critical patent/SG11202011139YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464429—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
SG11202011139YA 2018-05-16 2019-05-16 Protein binding nkg2d, cd16 and a fibroblast activation protein SG11202011139YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862672299P 2018-05-16 2018-05-16
PCT/US2019/032582 WO2019222449A1 (en) 2018-05-16 2019-05-16 Protein binding nkg2d, cd16 and a fibroblast activation protein

Publications (1)

Publication Number Publication Date
SG11202011139YA true SG11202011139YA (en) 2020-12-30

Family

ID=68540990

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202011139YA SG11202011139YA (en) 2018-05-16 2019-05-16 Protein binding nkg2d, cd16 and a fibroblast activation protein

Country Status (11)

Country Link
US (1) US20210363261A1 (en)
EP (1) EP3793605A4 (en)
JP (2) JP7494129B2 (en)
KR (1) KR20210010508A (en)
CN (1) CN112423788A (en)
AU (1) AU2019271263A1 (en)
BR (1) BR112020023299A2 (en)
CA (1) CA3100234A1 (en)
MX (1) MX2020012273A (en)
SG (1) SG11202011139YA (en)
WO (1) WO2019222449A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018219887B2 (en) 2017-02-08 2024-08-15 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
CA3235295A1 (en) 2017-02-20 2018-08-23 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
US11884733B2 (en) 2018-02-08 2024-01-30 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the NKG2D receptor
EP4284518A1 (en) * 2021-01-27 2023-12-06 Georgetown University Fibroblast activation protein modulation to alter immune cell migration and tumor infiltration
EP4311557A1 (en) * 2022-07-26 2024-01-31 Oncomatryx Biopharma, S.L. Fap-targeted antibody-drug conjugates

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2623109C (en) * 2005-10-14 2019-02-19 Innate Pharma Nk cell-depleting antibodies for treating immunoproliferative disorders
PL2222706T5 (en) * 2007-12-14 2017-09-29 Novo Nordisk As Antibodies against human nkg2d and uses thereof
WO2010017103A2 (en) * 2008-08-04 2010-02-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Fully human anti-human nkg2d monoclonal antibodies
UY32808A (en) 2009-07-29 2011-02-28 Abbott Lab IMMUNOGLOBULINS AS A DUAL VARIABLE DOMAIN AND USES OF THE SAME
LT2603530T (en) * 2010-08-13 2018-01-25 Roche Glycart Ag Anti-fap antibodies and methods of use
US9718893B2 (en) * 2011-12-19 2017-08-01 Synimmune Gmbh Bispecific antibody molecule
JP2018503399A (en) * 2015-01-14 2018-02-08 コンパス セラピューティクス リミテッド ライアビリティ カンパニー Multispecific immunomodulatory antigen-binding construct
WO2016207273A2 (en) * 2015-06-23 2016-12-29 Innate Pharma Multispecific antigen binding proteins
US20190031785A1 (en) 2016-01-13 2019-01-31 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
AU2017238172B2 (en) * 2016-03-21 2024-06-27 Marengo Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
JP2018035137A (en) * 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ Novel anti-fibroblast activated protein (FAP) binding agent and use thereof
AU2018219887B2 (en) * 2017-02-08 2024-08-15 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
US20200216544A1 (en) * 2017-08-16 2020-07-09 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16, and egfr, hla-e, ccr4, or pd-l1

Also Published As

Publication number Publication date
EP3793605A1 (en) 2021-03-24
JP2023182838A (en) 2023-12-26
JP7494129B2 (en) 2024-06-03
EP3793605A4 (en) 2022-03-30
BR112020023299A2 (en) 2021-02-02
JP2021523913A (en) 2021-09-09
WO2019222449A8 (en) 2020-12-10
CA3100234A1 (en) 2019-11-21
US20210363261A1 (en) 2021-11-25
MX2020012273A (en) 2021-04-28
AU2019271263A1 (en) 2020-12-03
CN112423788A (en) 2021-02-26
WO2019222449A1 (en) 2019-11-21
KR20210010508A (en) 2021-01-27

Similar Documents

Publication Publication Date Title
IL280673A (en) Proteins binding nkg2d, cd16 and a tumor-associated antigen
SG11202011139YA (en) Protein binding nkg2d, cd16 and a fibroblast activation protein
IL270794A (en) A protein binding nkg2d, cd16 and ror1 or ror2
IL281323A (en) Proteins binding nkg2d, cd16 and a tumor-associated antigen
IL281305A (en) Proteins binding nkg2d, cd16, and egfr, ccr4, or pd-l1
IL268567A (en) Proteins binding bcma, nkg2d and cd16
IL268755A (en) Proteins binding her2, nkg2d and cd16
IL292261A (en) Proteins binding nkg2d, cd16 and flt3
EP4146271A4 (en) Proteins binding nkg2d, cd16 and clec12a
IL268790A (en) Proteins binding cd33, nkg2d and cd16
IL270803A (en) A protein binding nkg2d, cd16 and a tumor-associated antigen
IL272706A (en) Proteins binding nkg2d, cd16 and a tumor-associated antigen
EP3681532A4 (en) Proteins binding nkg2d, cd16, and c-type lectin-like molecule-1 (cll-1)
IL270801A (en) A protein binding nkg2d, cd16 and a tumor-associated antigen
IL272374A (en) Proteins binding nkg2d, cd16 and flt3
IL268574A (en) Proteins binding psma, nkg2d and cd16
IL268768A (en) Proteins binding gd2, nkg2d and cd16
IL280656A (en) Multi-specific binding proteins that bind her2, nkg2d, and cd16, and methods of use
IL268766A (en) Proteins binding cd123, nkg2d and cd16
IL280618A (en) Proteins binding nkg2d, cd16 and a tumor-associated antigen
EP3790585A4 (en) A protein binding nkg2d, cd16 and a tumor-associated antigen
ZA201905273B (en) Proteins binding psma, nkg2d and cd16